[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Moves -0.05%: What You Should Know",
    "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $778.62, indicating a -0.05% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=e038d6754bc4ce95d2b31edf84376355aff54f39c5cdd780c90989e4e9eebbe2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734475520,
      "headline": "Eli Lilly (LLY) Stock Moves -0.05%: What You Should Know",
      "id": 132033778,
      "image": "https://media.zenfs.com/en/zacks.com/2f0d6efdd8740952a371c97ddea6e926",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Eli Lilly (LLY) closed at $778.62, indicating a -0.05% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=e038d6754bc4ce95d2b31edf84376355aff54f39c5cdd780c90989e4e9eebbe2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Alzheimer's treatment approved in China",
    "summary": "China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January, the company...",
    "url": "https://finnhub.io/api/news?id=a90cfd1bc7413f911b48be795438328091306a17a57b989361e8dc775b3b7a22",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734468633,
      "headline": "Eli Lilly's Alzheimer's treatment approved in China",
      "id": 132033437,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option after Eisai and Biogen's Leqembi received approval in January, the company...",
      "url": "https://finnhub.io/api/news?id=a90cfd1bc7413f911b48be795438328091306a17a57b989361e8dc775b3b7a22"
    }
  },
  {
    "ts": null,
    "headline": "NVS vs. LLY: Which Stock Should Value Investors Buy Now?",
    "summary": "NVS vs. LLY: Which Stock Is the Better Value Option?",
    "url": "https://finnhub.io/api/news?id=f0ab1413e955a4b19018d0adcf5038ef218923d8509e43ef9a29aa47ef780917",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734453608,
      "headline": "NVS vs. LLY: Which Stock Should Value Investors Buy Now?",
      "id": 132033780,
      "image": "https://media.zenfs.com/en/zacks.com/26a86d59f0e8f1e82a35a92ae5684cd9",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVS vs. LLY: Which Stock Is the Better Value Option?",
      "url": "https://finnhub.io/api/news?id=f0ab1413e955a4b19018d0adcf5038ef218923d8509e43ef9a29aa47ef780917"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
    "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=5a966c02a1d0bc1ef39b4c2a7e83c71414773241faa5cd4535c00a6a6fdef9d7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734453180,
      "headline": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
      "id": 132064405,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=5a966c02a1d0bc1ef39b4c2a7e83c71414773241faa5cd4535c00a6a6fdef9d7"
    }
  },
  {
    "ts": null,
    "headline": "Palantir’s high valuation paints a stark picture of the S&P 500’s priciest picks",
    "summary": "You have probably seen warnings that after two years of double-digit gains for the S 500, stocks are getting pricey. Then again, you find warnings that the sky is about to fall down every day in the financial media.",
    "url": "https://finnhub.io/api/news?id=10eb2f309f33733267e98c93d7d8523e8915626cbf11d6390afd75274326dfca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734450900,
      "headline": "Palantir’s high valuation paints a stark picture of the S&P 500’s priciest picks",
      "id": 132039125,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "You have probably seen warnings that after two years of double-digit gains for the S 500, stocks are getting pricey. Then again, you find warnings that the sky is about to fall down every day in the financial media.",
      "url": "https://finnhub.io/api/news?id=10eb2f309f33733267e98c93d7d8523e8915626cbf11d6390afd75274326dfca"
    }
  },
  {
    "ts": null,
    "headline": "4 Big Drug Stocks That May Continue to Outperform in 2025",
    "summary": "Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.",
    "url": "https://finnhub.io/api/news?id=a277ac74285e35a4058bef9b5847ee67e8a6e3f755b62cdb97bbd019beb98daf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734447780,
      "headline": "4 Big Drug Stocks That May Continue to Outperform in 2025",
      "id": 132026658,
      "image": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Gilead, Eli Lilly, Vertex Pharmaceuticals and AbbVie have outperformed the industry this year and are likely to see continued momentum in 2025.",
      "url": "https://finnhub.io/api/news?id=a277ac74285e35a4058bef9b5847ee67e8a6e3f755b62cdb97bbd019beb98daf"
    }
  },
  {
    "ts": null,
    "headline": "15 Billion Reasons to Love Eli Lilly Stock Right Now",
    "summary": "Lilly just gave investors more reasons to cheer the company on.",
    "url": "https://finnhub.io/api/news?id=630f0868005d027177942f8e328ac190ca617b00006e07a9bfa2b2331c20abf1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734446700,
      "headline": "15 Billion Reasons to Love Eli Lilly Stock Right Now",
      "id": 132026659,
      "image": "https://g.foolcdn.com/editorial/images/801051/gettyimages-1158906702-3.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly just gave investors more reasons to cheer the company on.",
      "url": "https://finnhub.io/api/news?id=630f0868005d027177942f8e328ac190ca617b00006e07a9bfa2b2331c20abf1"
    }
  },
  {
    "ts": null,
    "headline": "IHF: Healthcare Dashboard For December",
    "summary": "iShares U.S. Healthcare Providers ETF presents a reasonable valuation. Learn why IHF stock stands out with cheaper healthcare stocks for December investment.",
    "url": "https://finnhub.io/api/news?id=25fd9f65de62fad6eae2cba2aa32748a230107bd178df713a24b7a9dcdb914ad",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734441311,
      "headline": "IHF: Healthcare Dashboard For December",
      "id": 132027739,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1308861166/image_1308861166.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "iShares U.S. Healthcare Providers ETF presents a reasonable valuation. Learn why IHF stock stands out with cheaper healthcare stocks for December investment.",
      "url": "https://finnhub.io/api/news?id=25fd9f65de62fad6eae2cba2aa32748a230107bd178df713a24b7a9dcdb914ad"
    }
  },
  {
    "ts": null,
    "headline": "Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt",
    "summary": "The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and analog insulin to at least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.",
    "url": "https://finnhub.io/api/news?id=94b891d843b8169c522cbcd14aea5ecdebd81966236e960b59b494c5346705ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734433200,
      "headline": "Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt",
      "id": 132024270,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and analog insulin to at least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa.",
      "url": "https://finnhub.io/api/news?id=94b891d843b8169c522cbcd14aea5ecdebd81966236e960b59b494c5346705ae"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: green light for insulin glargine in Egypt",
    "summary": "Eli Lilly has announced that the Egyptian Medicines Authority has approved the insulin glargine injection manufactured by EVA Pharma in collaboration with Eli Lilly and Company. This collaboration,...",
    "url": "https://finnhub.io/api/news?id=03c7c93572e16bf655f9d6d59a2e65542e68768d0df1ea3185155e11479d7212",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734423859,
      "headline": "Eli Lilly: green light for insulin glargine in Egypt",
      "id": 132024133,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly has announced that the Egyptian Medicines Authority has approved the insulin glargine injection manufactured by EVA Pharma in collaboration with Eli Lilly and Company. This collaboration,...",
      "url": "https://finnhub.io/api/news?id=03c7c93572e16bf655f9d6d59a2e65542e68768d0df1ea3185155e11479d7212"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi sues HHS to defend 340B rebate policy",
    "summary": "The drugmaker is following in the footsteps of Johnson & Johnson and Eli Lilly in filing suit to force through controversial reforms to the drug discount program, against the wishes of federal regulators.",
    "url": "https://finnhub.io/api/news?id=558ccc24b0ae769f76b3d1258f07f5bf4a2cf027a4a321e659349a6b3b5d28cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734423682,
      "headline": "Sanofi sues HHS to defend 340B rebate policy",
      "id": 132026661,
      "image": "https://imgproxy.divecdn.com/_guXm2owHLVe0u079ZedNQ-9srmiaDaaazJavTltJwg/g:nowe:189:144/c:1776:1003/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS80OTY5MDc4MzcxMl8yYTc1ZmQ5M2MyX28uanBn.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker is following in the footsteps of Johnson & Johnson and Eli Lilly in filing suit to force through controversial reforms to the drug discount program, against the wishes of federal regulators.",
      "url": "https://finnhub.io/api/news?id=558ccc24b0ae769f76b3d1258f07f5bf4a2cf027a4a321e659349a6b3b5d28cd"
    }
  },
  {
    "ts": null,
    "headline": "The Stock Market Is One Big Contradiction Right Now. What That Means for 2025 and 5 Other Things to Know Today.",
    "summary": "The Stock Market Is One Big Contradiction Right Now. What That Means for 2025 and 5 Other Things to Know Today.",
    "url": "https://finnhub.io/api/news?id=9d46383e91b0c5fe3c1f0607dc9671718e986e44cddc4be5509fa75313498b29",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734417540,
      "headline": "The Stock Market Is One Big Contradiction Right Now. What That Means for 2025 and 5 Other Things to Know Today.",
      "id": 132063848,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "The Stock Market Is One Big Contradiction Right Now. What That Means for 2025 and 5 Other Things to Know Today.",
      "url": "https://finnhub.io/api/news?id=9d46383e91b0c5fe3c1f0607dc9671718e986e44cddc4be5509fa75313498b29"
    }
  },
  {
    "ts": null,
    "headline": "Mairs & Power Balanced Fund Q3 2024 Commentary",
    "summary": "The Mairs & Power Balanced Fund finished the first nine months of 2024 up 11.02%. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=8eddadab94cf3228ebe784eeed3079bc85159393428d030a121432591eb155b2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734417300,
      "headline": "Mairs & Power Balanced Fund Q3 2024 Commentary",
      "id": 132023135,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/955408614/image_955408614.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Mairs & Power Balanced Fund finished the first nine months of 2024 up 11.02%. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=8eddadab94cf3228ebe784eeed3079bc85159393428d030a121432591eb155b2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: A Rare Buying Opportunity",
    "summary": "Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock a strong buy.",
    "url": "https://finnhub.io/api/news?id=6001b19f3bccbe1845e8df7fc40e6f760ea0f9d897e4ed119753b473128ab105",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734416411,
      "headline": "Eli Lilly: A Rare Buying Opportunity",
      "id": 132023080,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1355656320/image_1355656320.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock a strong buy.",
      "url": "https://finnhub.io/api/news?id=6001b19f3bccbe1845e8df7fc40e6f760ea0f9d897e4ed119753b473128ab105"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Caution Ahead Of Novo's CagriSema Readout (Rating Downgrade)",
    "summary": "The obesity treatment market is dominated by Eli Lilly and Novo Nordisk, making it challenging for Viking. Read why I recommend Hold for VKTX stock.",
    "url": "https://finnhub.io/api/news?id=23d72f23aa68ee5c6766b4e5d65123024dbb56b516729f9ecb8815623623380e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734400264,
      "headline": "Viking Therapeutics: Caution Ahead Of Novo's CagriSema Readout (Rating Downgrade)",
      "id": 132020726,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175904373/image_2175904373.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The obesity treatment market is dominated by Eli Lilly and Novo Nordisk, making it challenging for Viking. Read why I recommend Hold for VKTX stock.",
      "url": "https://finnhub.io/api/news?id=23d72f23aa68ee5c6766b4e5d65123024dbb56b516729f9ecb8815623623380e"
    }
  }
]